Christopher Evans, M.D.

Christopher P. Evans, M.D.



Urologic Oncology





  • Chair, Department of Urology
  • Professor
To see if Christopher P. Evans is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).

Lawrence J. Ellison Ambulatory Care Center

4860 Y St., Suite 2200
Sacramento, CA 95817
Driving Directions

Primary Phone:

UC Davis Comprehensive Cancer Center

2279 45th Street
Sacramento, CA 95817
Driving Directions

Primary Phone:

4501 X St.
Sacramento, CA 95817
Driving Directions

Primary Phone:

Additional Phone Numbers

Physician Referrals: 800-362-5566

Philosophy of Care

Dr. Evans' philosophy of care is to:

  • fully assess the patient's medical condition, including how it relates to family and social circumstances;
  • educate the patient fully about their disease process; and
  • include the patient in the decision-making process that best suits the outcomes they seek.

In each case he looks for opportunity to enroll them in any new therapies or clinical trials that may be available and pertinent.

Clinical Interests

Dr. Evans' practice is dedicated to the management of patients with urologic malignancies. He works with medical oncologists and radiation oncologists to provide multimodal approaches to cancer therapy.

His surgical expertise includes robotic assisted laparoscopic radical prostatectomy with nerve sparing, complex renal surgery to include partial nephrectomy and vena cava thrombectomy, cystectomy with extended pelvic lymph node dissection and urinary diversion with orthotopic neobladders.

Dr. Evans also has expertise in treating patients with metastatic testicular cancer and performing retroperitoneal lymph node dissection in post chemotherapy patients.

Research/Academic Interests

Dr. Evans' research laboratory focuses on prostate cancer; specifically, mechanisms signaling the androgen receptor to activate prostate cancer growth and progression following castration. His laboratory has developed models to study this and has identified novel mechanisms that activate the androgen receptor.

His laboratory work has tested new agents and brought them from bench studies to animal models to clinical trials.



Center/Program Affiliation

Robotic Surgery Program
UC Davis Comprehensive Cancer Center


M.D., F.A.C.S., Dartmouth Medical School, Hanover, New Hampshire, 1986

B.A., University of Vermont, Burlington, Vermont, 1981


University of California, San Francisco, San Francisco, California, 1990-91

University of California, San Francisco, San Francisco, California, 1991-95


University of California, San Francisco National Kidney Foundation Research Fellow, San Francisco, California, 1993-94

University of Texas, Anderson Cancer Center, Houston, Texas, 1995-97

Board Certifications

American Board of Urology, 1999

American College of Surgeons, 2000

National Board of Medical Examiners, 1987

Professional Memberships

American Association for Cancer Research

American Association for the Advancement of Science

American Association of Genitourinary Surgeons

American College of Surgeons

American Society of Clinical Oncology

American Urology Association

Association of Military Surgeons of the United States

European Association of Urology

Society for Basic Urologic Research

Society of Government Urologists

Society of Urologic Oncology

Southwest Oncology Group

Uniformed Services University

Honors and Awards

American Association of Genitourinary Surgeons, Elected Membership, 2009

Western Section AUA nominee for the Gold Cystoscope Award, 2005

1st Prize, Joseph F. McCarthy Essay Contest of the American Urological Association, 2003

Finalist, California Cancer Research Program Gerald P. Murphy Award, 2001

Third Place Award for Basic Science, University of California, Davis Cancer Center Symposium, 1998

Mortar Board Honor Society, 1998

Honorable Mention, AUA Circon/ACMI Essay Contest, Laboratory Research, 1996

Recipient NIH Travel Award Grant, Keystone Symposia on Molecular and Cellular Biology "Breast and Prostate Cancer: Basic Mechanisms", 1996

First Place Award for Basic Science, Society for University Urology Residents, National Chief Resident Meeting, 1995

Recipient, American Association for Cancer Research Young Investigator Award, "Basic and Clinical Aspects of Prostate Cancer", 1994

Northern California Urology Residents' Competition, First Place Award for Basic Science, 1994

Northern California Urology Residents' Competition, Second Place Award for Basic Science, 1993

Recipient, American Association for Cancer Research/National Cancer Institute Travel Grant. Molecular Biology Workshop, Aspen, CO, 1993

Northern California Urology Residents' Competition, Second Place Award for Basic Science, 1992

Northern California Urology Residents' Competition, First Place Award for Basic Science, 1991

Recipient, Army Commendation Medal, 1990

Finalist, Army Science Conference Competition, 1990

Select Recent Publications

Lara PN Jr, Evans CP. Dasatinib and Docetaxel in Advanced Prostate Cancer. Lancet Oncology. Epub ahead of print.

Dall’Era, M., Evans C.P., Wu, J., de Vere White R. No Improvement in Overall or Cause Specific Survival for Men Presenting with Metastatic Prostate Cancer over a 20 Year period. Cancer. In press.

Guo, W, Liu, R, Bhardwaj, G, Ma, AH, Changou, C, Yang, JC, Li, Y, Feng, C, Luo, Y, Mazloom, A, Sanchez, E, Wang, Y, Huang, W, Patterson, R, Evans, CP, Lam, KS, Kung, HJ. CTA095, a Novel Etk and Src Dual Inhibitor, Induces Apoptosis in Prostate Cancer Cells and Overcomes Resistance to Src Inhibitors. PloS One, 8(8): e70910.

Tilki, D., Nguyen H., Dall’Era, M., Bertini, R., Carballlido, J., Chromecki, T., Ciancio, G., Daneshmand, S., Gontero, P., Gonzalez J., Haferkamp A., Hohenfellner, M., Huang, W., Koppie, T., Lorentz, A., Martinez-Salamanca, J., Master, V., Matloob, R., McKiernan, J., Mlynarczyk, C., Montorsi, F., Novara, G., Pahernik, S., Palou, J., Pruthi, R., Ramaswamy, K., Faba, O., Russo, P., Shariat, S., Spahn, M., Terrone, C., Vergho, D., Wallen, E., Xylinas, E., Zigeuner, R., Libertino, J., Evans, C.P. Impact of HIstologic Subtype on Cancer-specific Survival in Patients with Renal Cell Carcinoma and Tumor Thrombus. European Association of Urology. 2013 Jul 10 [Epub ahead of print]

Liuqing Yang, Chunru Lin, Chunyu Jin, Joy C. Yang, Bogdan Tanasa, Wenbo Li,, Daria Merkurjev, Kenneth A. Ohgi, Da Meng, Jie Zhang, Christopher P. Evans & Michael G. Rosenfeld. LncRNA-Dependent Mechanisms of Androgen Receptor-regulated Gene Activation Programs. Nature. 2013 Aug 2;500:598-602.

Zhu, Y, Liu, C, Nadimity, N, Lou, W, Tummala, R, Evans, CP, Gao, AC. Inhibition of ABCB1 Expression Overcomes Acquired Docetaxel Resistance in Prostate Cancer. Molecular Cancer Therapeutics. 2013 Sep;12(9):1829-36.

Tummala, R, Nadiminty, N, Lou, W, Zhu, Y, Gandour-Edwards, R, Chen, HW, Evans, CP, Gao, AC. Lin28 promotes growth of prostate cancer cells and activates the androgen receptor. Am J Pathol, 183(1): 288-95.

Kao, CJ, Martiniez, A, Shi, XB, Yang, J, Evans, CP, Dobi, A, Devere White, RW, Kung, HJ. MiR-30 as a tumor suppressor connects EGF/Src signal to ERG and EMT. Oncogene. 2013 Jun 3. [epub ahead of print].

Nadiminty N, Tummala R, Liu C, Yang J, Lou W, Evans CP, Gao AC. NF-kappaB2/p52 induces resistance to Enzalutamide in Prostate Cancer: Role of androgen receptor and its variants. Mol Cancer Ther. 2013 May 22. [Epub ahead of print]

Tilki D, Brausi M, Colombo R, Evans CP, Fradet Y, Fritsche HM, Lerner SP, Sagalowsky A, Shariat SF, Bochner BH. Lymphadenectomy for Bladder Cancer at the Time of Radical Cystectomy. Eur Urol. 2013 Apr 29. pii: S0302-2838(13)00421-1. doi: 10.1016/j.eururo.2013.04.036. [Epub ahead of print]

Inoue H, Kauffman M, Shacham S, Landesman Y, Yang J, Evans CP, Weiss RH. CRM1 Blockade by Selective Inhibitors of Nuclear Export Attenuates Kidney Cancer Growth. J Urol. 2013 Jun;189(6):2317-26. doi: 10.1016/j.juro.2012.10.018. Epub 2012 Oct 16.

Keegan, KA, Schupp, CW, Chamie, K, Hellenthal, NJ, Evans, CP, Koppie, TM. Histopathology of Surgically Treated Renal Cell Carcinoma: Survival Differences by Subtype and Stage. The Journal of Urology. 2012 Aug;188(2):391-7